PTPN11 and diabetes mellitus: Recently Choi et al. found that the SHP2-MAPK pathway regulates insulin receptor endocytosis such that SHP2 inhibition prolongs insulin action and improves insulin sensitivity, suggesting that SHP2 is also a valuable therapeutic target for diabetes.9–11